<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03038113</url>
  </required_header>
  <id_info>
    <org_study_id>BP39405</org_study_id>
    <nct_id>NCT03038113</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study will be conducted in two parts to evaluate the safety, tolerability,&#xD;
      pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931. Part 1&#xD;
      will include only healthy participants and Part 2 will include only participants with chronic&#xD;
      hepatitis B (CHB). Part 1 is an adaptive, single-ascending dose study with an adaptive&#xD;
      dose-escalating schedule to determine the best dose to be evaluated in participants with CHB.&#xD;
      Part 2 is an adaptive, parallel multiple-dose study comprised of three sub-parts which will&#xD;
      be used to further refine the dose and dosing regimen, and to evaluate the safety and&#xD;
      efficacy of RO7062931 when administered with standard-of-care (SoC) therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">October 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest</measure>
    <time_frame>Up to day 113</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.&#xD;
AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation ≥10x ULN, v.) creatinine elevation ≥1.5x ULN or ≥50% from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1</measure>
    <time_frame>Screening, Days -1, 2, 8, 15, 29, 85</time_frame>
    <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2</measure>
    <time_frame>Screening, Days -1, 2, 8, 15, 29, at discontinuation, Days 36, 43, 57, 85, 113</time_frame>
    <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1</measure>
    <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
    <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2</measure>
    <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
    <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1</measure>
    <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
    <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1</measure>
    <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
    <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2</measure>
    <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
    <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2</measure>
    <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
    <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2</measure>
    <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
    <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1,22,29</time_frame>
    <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>AUC0-last was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1,22,29</time_frame>
    <description>AUC0-last was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>T1/2 was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>T1/2 was calculated based on non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance (CL) After Single Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Clearance (CL) After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vss) After Single Ascending Doses - Part 1</measure>
    <time_frame>Days 1-8</time_frame>
    <description>Vss was calculated from dose/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>Vss was calculated from dose/AUCinf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1</measure>
    <time_frame>Hours 0-4, 0-8, 0-12, and 0-24</time_frame>
    <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2</measure>
    <time_frame>Days 1-113</time_frame>
    <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2</measure>
    <time_frame>Day 1 - Day 113</time_frame>
    <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Time to Maximum qHBsAg Decrease on Day 1-113 - Part 2</measure>
    <time_frame>Day 1 - Day 113</time_frame>
    <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Part 1: Single-Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7062931</intervention_name>
    <description>Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.</description>
    <arm_group_label>Part 1: Single-Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Part 2: Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.</description>
    <arm_group_label>Part 1: Single-Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Part 2: Multiple Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Modulator</intervention_name>
    <description>Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.</description>
    <arm_group_label>Part 2: Multiple Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        FOR HEALTHY VOLUNTEERS ONLY - PART 1 -&#xD;
&#xD;
          -  A Body Mass Index (BMI) between 18 to 30 kg/m2 inclusive and a body weight of at least&#xD;
             50 kg.&#xD;
&#xD;
          -  Women should be of non-childbearing potential. A woman is considered to be of&#xD;
             childbearing potential if she is post-menarcheal but has not reached a post-menopausal&#xD;
             state and has not undergone surgical sterilization (removal of ovaries and/or uterus).&#xD;
&#xD;
          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures during treatment and up to 105 days after the last dose, and&#xD;
             agree to refrain from donating sperm.&#xD;
&#xD;
          -  Non-smoker (nor tobacco containing products) for at least 90 days prior to dosing on&#xD;
             Day 1 and agree to remain as non-smoker during the study.&#xD;
&#xD;
        FOR CHB PARTICIPANTS ONLY - PARTS 2a and 2b:&#xD;
&#xD;
          -  A BMI between 18 to 32 kg/m2 inclusive.&#xD;
&#xD;
          -  Chronic hepatitis B (HBV) infection.&#xD;
&#xD;
          -  Positive test for HBsAg for more than 6 months prior to randomization and HBsAg titer&#xD;
             ≥ 10^3 IU/mL at screening.&#xD;
&#xD;
          -  On entecavir, tenofovir, adefovir or telbivudine treatment for at least 6 months prior&#xD;
             to randomization and will remain on stable treatment during the study.&#xD;
&#xD;
          -  HBV deoxyribonucleic acid (DNA) ≤ 90 IU/mL for at least the preceding 6 months.&#xD;
&#xD;
          -  Screening laboratory values (hematology, chemistry, urinalysis) obtained up to 56 days&#xD;
             prior to first study treatment within normal ranges.&#xD;
&#xD;
          -  Liver biopsy, fibroscan® or equivalent test obtained within the past 6 months&#xD;
             demonstrating liver disease consistent with chronic HBV infection without evidence of&#xD;
             bridging fibrosis or cirrhosis&#xD;
&#xD;
          -  Women should be of non-childbearing potential. A woman is considered to be of&#xD;
             childbearing potential if she is post-menarcheal but has not reached a post-menopausal&#xD;
             state and has not undergone surgical sterilization (removal of ovaries and/or uterus).&#xD;
&#xD;
          -  Men must agree to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive measures during treatment and up to 105 days after the last dose, and&#xD;
             agree to refrain from donating sperm.&#xD;
&#xD;
        FOR CHB PARTICIPANTS ONLY - PART 2c&#xD;
&#xD;
          -  BMI between 18 to 32 kg/m2 inclusive&#xD;
&#xD;
          -  CHB infection (HBsAg-positive for at least 6 months)&#xD;
&#xD;
          -  For NUC-suppressed CHB participants: Must have been treated with a single NUC for at&#xD;
             least 12 months, and have been on the same NUC therapy for at least 3 months prior to&#xD;
             screening; HBV DNA &lt;lower limit of quantification (LLOQ) at screening and in the 6&#xD;
             months prior to screening (at least one measurement must be &gt;30 days prior to&#xD;
             screening); alanine aminotransferase (ALT) &lt;/=2x upper limit of normal (ULN) for &gt;6&#xD;
             months prior to screening and confirmed at screening; total bilirubin within normal&#xD;
             range at screening, except for patients with Gilbert's syndrome&#xD;
&#xD;
          -  For treatment-naive and immune-active participants: HBV DNA at screening &gt;/=2x10^4&#xD;
             IU/mL for HBeAg positive participants, or &gt;/=2x10^3 IU/mL for HBeAg negative&#xD;
             participants; elevated serum ALT&gt;2 ULN to &lt;/=5, 2 values within 6 months, at least one&#xD;
             of which is at screening and that are at least 14 days apart; total bilirubin within&#xD;
             normal range except for participants with Gilbert's syndrome&#xD;
&#xD;
          -  Screening laboratory values (hematology, chemistry, urinalysis) obtained up to 28 days&#xD;
             prior to first study treatment within normal ranges&#xD;
&#xD;
          -  Liver biopsy, fibroscan, or equivalent test obtained within the last 6 months&#xD;
             demonstrating liver disease consistent with chronic HBV infection without evidence of&#xD;
             bridging fibrosis or cirrhosis&#xD;
&#xD;
          -  Women should be of non-childbearing potential&#xD;
&#xD;
          -  Men must agree to remain abstinent or use contraception, and agree to refrain from&#xD;
             donating sperm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        FOR HEALTHY VOLUNTEERS ONLY - PART 1:&#xD;
&#xD;
          -  History of drug or alcohol abuse or dependence in previous 6 months.&#xD;
&#xD;
          -  Positive urine drug and alcohol screen or positive cotinine test at screening or Day&#xD;
             -1.&#xD;
&#xD;
          -  Positive result on hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency&#xD;
             virus (HIV) 1 and 2.&#xD;
&#xD;
          -  Confirmed blood pressure or resting pulse rate outside of accepted ranges.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 90 days prior to&#xD;
             screening.&#xD;
&#xD;
          -  Donation of blood over 500 mL within three months prior to screening.&#xD;
&#xD;
          -  Any major illness within the one month, or any febrile illness within two weeks&#xD;
             preceding the screening visit.&#xD;
&#xD;
          -  Alcohol consumption of more than 2 standard drinks per day on average.&#xD;
&#xD;
        FOR CHB PARTICIPANTS ONLY - PARTS 2a and 2b:&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices.&#xD;
&#xD;
          -  Decompensated liver disease.&#xD;
&#xD;
          -  History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) ≥ 13&#xD;
             ng/mL at Screening&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV infection.&#xD;
&#xD;
          -  Documented history or other evidence of metabolic liver disease within one year of&#xD;
             randomization or documented history of infection with hepatitis D virus.&#xD;
&#xD;
          -  Positive test for hepatitis A (IgM anti-HAV), hepatitis C, or HIV.&#xD;
&#xD;
          -  Organ transplantation.&#xD;
&#xD;
          -  Significant acute infection or any other clinically significant illness within 2 weeks&#xD;
             of randomization.&#xD;
&#xD;
          -  Abnormal renal function.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 30 days prior to&#xD;
             randomization.&#xD;
&#xD;
          -  Donation or loss of blood over 500 mL within 3 months prior to starting study&#xD;
             medication.&#xD;
&#xD;
          -  Administration of any blood product within 3 months of randomization.&#xD;
&#xD;
          -  History or evidence of alcohol abuse (consumption of more than 2 standard drinks per&#xD;
             day on average).&#xD;
&#xD;
        FOR CHB PARTICIPANTS ONLY - PART 2c&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices&#xD;
&#xD;
          -  Evidence of liver cirrhosis or decompensated liver disease&#xD;
&#xD;
          -  One or more of the following laboratory abnormalities at screening: Total serum&#xD;
             bilirubin &gt; ULN (except for participants with Gilbert's disease); international&#xD;
             normalized ratio (INR) &gt; 1.1 ULN; serum albumin &lt; 3.5 g/dL; AFP &gt;13 ng/mL; positive&#xD;
             results for anti-mitochondrial antibodies (AMA &gt; 1:80), anti-nuclear antibody (ANA &gt;&#xD;
             1:80), anti-smooth muscle antibody (ASMA &gt; 1:40), anti-thyroperoxidase antibodies&#xD;
             (a-TPO), anti-thyroglobulin, or anti-platelet antibodies; thyroid stimulating hormone&#xD;
             (TSH) outside of normal range; platelet count &lt;100,000 cells/mm^3; hemoglobin &lt;12 g/dL&#xD;
             (females) or &lt;13 g/dL (males); white blood cell count &lt;2500 cells/mm^3; and neutrophil&#xD;
             count &lt;1500 cells/mm^3&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HBV infection&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications or clinically&#xD;
             relevant abnormal thyroid function tests&#xD;
&#xD;
          -  Documented history or other evidence of metabolic liver disease within one year of&#xD;
             randomization&#xD;
&#xD;
          -  Positive test for hepatitis A, hepatitis C, or HIV&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 30 days prior to&#xD;
             screening or previous treatment with an investigational agent for HBV within 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Significant acute infection or any other clinically significant illness within 2 weeks&#xD;
             of randomization&#xD;
&#xD;
          -  Abnormal renal function, including serum creatinine &gt; ULN or calculated creatinine&#xD;
             clearance &lt; 70 mL/min&#xD;
&#xD;
          -  Donation or loss of blood over 500 mL within 3 months prior to randomization&#xD;
&#xD;
          -  Administration of any blood product within 3 months prior to randomization&#xD;
&#xD;
          -  History of alcohol abuse and/or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Gangwon-Do</city>
        <zip>200-704</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChungAng University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulsan College of Medicine, Asan Medical Center, Digestive Disease Center</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Auckland</city>
        <zip>1142</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital; Dept of Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital; Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation - Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation Linkou Branch</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital; Dept. of Medicine</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <results_first_submitted>October 14, 2020</results_first_submitted>
  <results_first_submitted_qc>November 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 24, 2020</results_first_posted>
  <last_update_submitted>November 30, 2020</last_update_submitted>
  <last_update_submitted_qc>November 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunomodulating Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03038113/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Part 1 - RO7062931 0.1 mg/kg</title>
          <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
        </group>
        <group group_id="P2">
          <title>Part 1 - RO7062931 0.3 mg/kg</title>
          <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
        </group>
        <group group_id="P3">
          <title>Part 1 - RO7062931 1.0 mg/kg</title>
          <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P4">
          <title>Part 1 - RO7062931 2.0 mg/kg</title>
          <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P5">
          <title>Part 1 - RO7062931 3.0 mg/kg</title>
          <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P6">
          <title>Part 1 - RO7062931 4.0 mg/kg</title>
          <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P7">
          <title>Part 1 - Placebo</title>
          <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
        </group>
        <group group_id="P8">
          <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
          <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="P9">
          <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="P10">
          <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P11">
          <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
          <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P12">
          <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
          <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P13">
          <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
          <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="P14">
          <title>Part 2 - Placebo</title>
          <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="14"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="14"/>
                <participants group_id="P12" count="7"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1 - RO7062931 0.1 mg/kg</title>
          <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
        </group>
        <group group_id="B2">
          <title>Part 1 - RO7062931 0.3 mg/kg</title>
          <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
        </group>
        <group group_id="B3">
          <title>Part 1 - RO7062931 1.0 mg/kg</title>
          <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B4">
          <title>Part 1 - RO7062931 2.0 mg/kg</title>
          <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B5">
          <title>Part 1 - RO7062931 3.0 mg/kg</title>
          <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B6">
          <title>Part 1 - RO7062931 4.0 mg/kg</title>
          <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B7">
          <title>Part 1 - Placebo</title>
          <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
        </group>
        <group group_id="B8">
          <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
          <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="B9">
          <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="B10">
          <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B11">
          <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
          <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B12">
          <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
          <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B13">
          <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
          <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="B14">
          <title>Part 2 - Placebo</title>
          <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
        </group>
        <group group_id="B15">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="8"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="7"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="14"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="4"/>
            <count group_id="B14" value="15"/>
            <count group_id="B15" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="11.9"/>
                    <measurement group_id="B2" value="29.0" spread="11.4"/>
                    <measurement group_id="B3" value="34.0" spread="11.4"/>
                    <measurement group_id="B4" value="30.4" spread="13.6"/>
                    <measurement group_id="B5" value="24.8" spread="7.9"/>
                    <measurement group_id="B6" value="23.4" spread="3.5"/>
                    <measurement group_id="B7" value="31.6" spread="9.0"/>
                    <measurement group_id="B8" value="42.0" spread="5.3"/>
                    <measurement group_id="B9" value="42.7" spread="11.1"/>
                    <measurement group_id="B10" value="47.8" spread="7.2"/>
                    <measurement group_id="B11" value="46.1" spread="12.1"/>
                    <measurement group_id="B12" value="44.9" spread="8.7"/>
                    <measurement group_id="B13" value="48.5" spread="6.9"/>
                    <measurement group_id="B14" value="44.7" spread="9.0"/>
                    <measurement group_id="B15" value="37.1" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="14"/>
                    <measurement group_id="B15" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="15"/>
                    <measurement group_id="B15" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest</title>
        <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.&#xD;
AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation ≥10x ULN, v.) creatinine elevation ≥1.5x ULN or ≥50% from baseline.</description>
        <time_frame>Up to day 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Placebo</title>
            <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
          </group>
          <group group_id="O8">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O9">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O10">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O11">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O12">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O13">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O14">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest</title>
          <description>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.&#xD;
AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation ≥10x ULN, v.) creatinine elevation ≥1.5x ULN or ≥50% from baseline.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="7"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="14"/>
                <count group_id="O12" value="7"/>
                <count group_id="O13" value="4"/>
                <count group_id="O14" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="37.5"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="87.5"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="58.3"/>
                    <measurement group_id="O8" value="33.3"/>
                    <measurement group_id="O9" value="85.7"/>
                    <measurement group_id="O10" value="66.7"/>
                    <measurement group_id="O11" value="71.4"/>
                    <measurement group_id="O12" value="57.1"/>
                    <measurement group_id="O13" value="75.0"/>
                    <measurement group_id="O14" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of Special Interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1</title>
        <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
        <time_frame>Screening, Days -1, 2, 8, 15, 29, 85</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Placebo</title>
            <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1</title>
          <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGOT/AST - High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride - Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol - Low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides - High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2</title>
        <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
        <time_frame>Screening, Days -1, 2, 8, 15, 29, at discontinuation, Days 36, 43, 57, 85, 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2</title>
          <description>Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SGPT/ALT - High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="14.3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGOT/AST - High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicorbonate HCO3 - Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Fasting - High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activated Partial Thromboplastin Time - High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides - High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1</title>
        <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
        <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single SC injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Placebo</title>
            <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1</title>
          <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 12h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="37.5"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 - 168h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="37.5"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="12.5"/>
                    <measurement group_id="O6" value="12.5"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="25.0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1</title>
        <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
        <time_frame>Days 1-8</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1</title>
          <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" spread="40.2"/>
                    <measurement group_id="O2" value="19.53" spread="28.1"/>
                    <measurement group_id="O3" value="41.69" spread="30.8"/>
                    <measurement group_id="O4" value="103.68" spread="34.0"/>
                    <measurement group_id="O5" value="312.53" spread="22.2"/>
                    <measurement group_id="O6" value="153.53" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax After Multiple Ascending Doses - Part 2</title>
        <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
        <time_frame>Days 1-113</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax After Multiple Ascending Doses - Part 2</title>
          <description>Cmax values are the the peak plasma concentration reached after administration of RO7062931.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>mg/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.17" spread="46.4"/>
                    <measurement group_id="O2" value="72.44" spread="57.8"/>
                    <measurement group_id="O3" value="169.56" spread="43.9"/>
                    <measurement group_id="O4" value="158.61" spread="37.9"/>
                    <measurement group_id="O5" value="218.05" spread="64.4"/>
                    <measurement group_id="O6" value="232.54" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.56" spread="69.1"/>
                    <measurement group_id="O2" value="82.11" spread="37.6"/>
                    <measurement group_id="O3" value="194.72" spread="15.8"/>
                    <measurement group_id="O4" value="164.83" spread="65.0"/>
                    <measurement group_id="O5" value="190.83" spread="35.6"/>
                    <measurement group_id="O6" value="250.72" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1</title>
        <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
        <time_frame>Days 1-8</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1</title>
          <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>Hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.50" upper_limit="2.00"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.50" upper_limit="6.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="2.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax After Multiple Ascending Doses - Part 2</title>
        <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
        <time_frame>Days 1-113</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax After Multiple Ascending Doses - Part 2</title>
          <description>Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>Hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" lower_limit="0.50" upper_limit="7.90"/>
                    <measurement group_id="O2" value="2.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.90" upper_limit="8.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.90" upper_limit="6.00"/>
                    <measurement group_id="O5" value="3.98" lower_limit="1.90" upper_limit="5.90"/>
                    <measurement group_id="O6" value="2.00" lower_limit="1.90" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.00" upper_limit="7.70"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="2.00" upper_limit="4.10"/>
                    <measurement group_id="O4" value="1.97" lower_limit="1.90" upper_limit="7.80"/>
                    <measurement group_id="O5" value="2.94" lower_limit="1.90" upper_limit="5.70"/>
                    <measurement group_id="O6" value="2.95" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1</title>
        <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1-8</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1</title>
          <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.21" spread="14.0"/>
                    <measurement group_id="O2" value="92.72" spread="14.1"/>
                    <measurement group_id="O3" value="308.48" spread="13.2"/>
                    <measurement group_id="O4" value="792.36" spread="19.1"/>
                    <measurement group_id="O5" value="2478.56" spread="8.7"/>
                    <measurement group_id="O6" value="1257.23" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-inf After Multiple Ascending Doses - Part 2</title>
        <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1,22,29</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf After Multiple Ascending Doses - Part 2</title>
          <description>AUC0-inf was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175.30" spread="6.9"/>
                    <measurement group_id="O2" value="567.07" spread="41.5"/>
                    <measurement group_id="O3" value="1606.49" spread="26.4"/>
                    <measurement group_id="O4" value="1434.39" spread="13.6"/>
                    <measurement group_id="O5" value="1857.98" spread="41.2"/>
                    <measurement group_id="O6" value="2371.66" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="2199.57" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180.34" spread="13.3"/>
                    <measurement group_id="O2" value="680.80" spread="8.8"/>
                    <measurement group_id="O3" value="1636.76" spread="11.0"/>
                    <measurement group_id="O4" value="1475.19" spread="30.3"/>
                    <measurement group_id="O5" value="1541.85" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1</title>
        <description>AUC0-last was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1-8</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single SC injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1</title>
          <description>AUC0-last was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>(hr*nmol/L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.10" spread="14.0"/>
                    <measurement group_id="O2" value="92.62" spread="14.1"/>
                    <measurement group_id="O3" value="310.69" spread="12.9"/>
                    <measurement group_id="O4" value="789.27" spread="19.1"/>
                    <measurement group_id="O5" value="2448.99" spread="8.1"/>
                    <measurement group_id="O6" value="1253.26" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-last After Multiple Ascending Doses - Part 2</title>
        <description>AUC0-last was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1,22,29</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-last After Multiple Ascending Doses - Part 2</title>
          <description>AUC0-last was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>hr*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147.30" spread="28.8"/>
                    <measurement group_id="O2" value="555.16" spread="34.8"/>
                    <measurement group_id="O3" value="1603.81" spread="26.4"/>
                    <measurement group_id="O4" value="1458.57" spread="12.9"/>
                    <measurement group_id="O5" value="1929.56" spread="49.9"/>
                    <measurement group_id="O6" value="2279.78" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="2195.18" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.35" spread="52.6"/>
                    <measurement group_id="O2" value="662.95" spread="20.5"/>
                    <measurement group_id="O3" value="1633.64" spread="11.0"/>
                    <measurement group_id="O4" value="1470.64" spread="30.5"/>
                    <measurement group_id="O5" value="1539.73" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1</title>
        <description>T1/2 was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1-8</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1</title>
          <description>T1/2 was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>Hours (h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="65.4"/>
                    <measurement group_id="O2" value="3.99" spread="38.3"/>
                    <measurement group_id="O3" value="44.32" spread="170.4"/>
                    <measurement group_id="O4" value="97.06" spread="35.9"/>
                    <measurement group_id="O5" value="115.24" spread="60.4"/>
                    <measurement group_id="O6" value="85.70" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2</title>
        <description>T1/2 was calculated based on non-compartmental analysis.</description>
        <time_frame>Days 1-113</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2</title>
          <description>T1/2 was calculated based on non-compartmental analysis.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>Hours (h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="13.1"/>
                    <measurement group_id="O2" value="18.81" spread="32.0"/>
                    <measurement group_id="O3" value="88.59" spread="94.1"/>
                    <measurement group_id="O4" value="NA" spread="NA">Insufficient data to estimate parameter.</measurement>
                    <measurement group_id="O5" value="37.96" spread="62.1"/>
                    <measurement group_id="O6" value="15.09" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.86" spread="107.8"/>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient data to estimate parameter.</measurement>
                    <measurement group_id="O3" value="119.45" spread="58.8"/>
                    <measurement group_id="O4" value="172.20" spread="26.7"/>
                    <measurement group_id="O5" value="62.08" spread="91.8"/>
                    <measurement group_id="O6" value="152.79" spread="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clearance (CL) After Single Ascending Doses - Part 1</title>
        <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
        <time_frame>Days 1-8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clearance (CL) After Single Ascending Doses - Part 1</title>
          <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.68" spread="21.3"/>
                    <measurement group_id="O2" value="35.97" spread="24.7"/>
                    <measurement group_id="O3" value="37.36" spread="29.9"/>
                    <measurement group_id="O4" value="26.9" spread="20.8"/>
                    <measurement group_id="O5" value="16.15" spread="18.4"/>
                    <measurement group_id="O6" value="23.46" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Clearance (CL) After Multiple Ascending Doses - Part 2</title>
        <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
        <time_frame>Days 1-113</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Clearance (CL) After Multiple Ascending Doses - Part 2</title>
          <description>Apparent oral clearance was calculated from Dose/AUCinf.</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.12" spread="10.2"/>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient data to estimate parameter.</measurement>
                    <measurement group_id="O3" value="18.12" spread="27.2"/>
                    <measurement group_id="O4" value="21.76" spread="42.0"/>
                    <measurement group_id="O5" value="19.37" spread="43.5"/>
                    <measurement group_id="O6" value="18.75" spread="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vss) After Single Ascending Doses - Part 1</title>
        <description>Vss was calculated from dose/AUCinf</description>
        <time_frame>Days 1-8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vss) After Single Ascending Doses - Part 1</title>
          <description>Vss was calculated from dose/AUCinf</description>
          <units>Liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.22" spread="61.2"/>
                    <measurement group_id="O2" value="206.96" spread="35.2"/>
                    <measurement group_id="O3" value="2389.08" spread="228.8"/>
                    <measurement group_id="O4" value="3767.16" spread="34.4"/>
                    <measurement group_id="O5" value="2684.87" spread="56.8"/>
                    <measurement group_id="O6" value="2900.19" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2</title>
        <description>Vss was calculated from dose/AUCinf</description>
        <time_frame>Days 1-113</time_frame>
        <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2</title>
          <description>Vss was calculated from dose/AUCinf</description>
          <population>The PK analysis population included participants that did not significantly violate eligibility criteria and/or deviate significantly from the protocol. Participants with incomplete or unavailable data were excluded from analysis.</population>
          <units>Liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.27" spread="119.8"/>
                    <measurement group_id="O2" value="NA" spread="NA">Insufficient data to estimate parameter.</measurement>
                    <measurement group_id="O3" value="3122.3" spread="46.8"/>
                    <measurement group_id="O4" value="5405.97" spread="53.8"/>
                    <measurement group_id="O5" value="1734.46" spread="86.9"/>
                    <measurement group_id="O6" value="4131.91" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1</title>
        <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
        <time_frame>Hours 0-4, 0-8, 0-12, and 0-24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single SC injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1</title>
          <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
          <units>pmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Accumulation Interval 0-4 (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6180.14" spread="85.0"/>
                    <measurement group_id="O2" value="17111.86" spread="29.4"/>
                    <measurement group_id="O3" value="50248.03" spread="97.0"/>
                    <measurement group_id="O4" value="108870.36" spread="95.4"/>
                    <measurement group_id="O5" value="317169.45" spread="62.1"/>
                    <measurement group_id="O6" value="206781.39" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accumulation Interval 0-8 (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9028.41" spread="50.4"/>
                    <measurement group_id="O2" value="25608.73" spread="25.2"/>
                    <measurement group_id="O3" value="117472.78" spread="52.5"/>
                    <measurement group_id="O4" value="202181.27" spread="80.6"/>
                    <measurement group_id="O5" value="930967.60" spread="42.2"/>
                    <measurement group_id="O6" value="458520.65" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accumulation Interval 0-12 (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10399.04" spread="40.7"/>
                    <measurement group_id="O2" value="28335.16" spread="27.6"/>
                    <measurement group_id="O3" value="143182.68" spread="42.8"/>
                    <measurement group_id="O4" value="249381.19" spread="72.6"/>
                    <measurement group_id="O5" value="1148178.69" spread="38.2"/>
                    <measurement group_id="O6" value="592833.26" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accumulation Interval 0-24 (h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11043.57" spread="38.9"/>
                    <measurement group_id="O2" value="29221.86" spread="28.6"/>
                    <measurement group_id="O3" value="155256.07" spread="38.9"/>
                    <measurement group_id="O4" value="275688.93" spread="68.3"/>
                    <measurement group_id="O5" value="1235241.74" spread="33.9"/>
                    <measurement group_id="O6" value="647368.11" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2</title>
        <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
        <time_frame>Days 1-113</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2</title>
          <description>Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.</description>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.45" spread="22.48"/>
                    <measurement group_id="O2" value="183.38" spread="67.53"/>
                    <measurement group_id="O3" value="587.05" spread="294.65"/>
                    <measurement group_id="O4" value="790.51" spread="402.06"/>
                    <measurement group_id="O5" value="615.33" spread="432.78"/>
                    <measurement group_id="O6" value="1146.02" spread="177.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2</title>
        <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
        <time_frame>Days 1-113</time_frame>
        <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2</title>
          <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
          <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline value</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.360"/>
                    <measurement group_id="O2" value="3.37" spread="0.272"/>
                    <measurement group_id="O3" value="3.37" spread="0.134"/>
                    <measurement group_id="O4" value="3.68" spread="0.381"/>
                    <measurement group_id="O5" value="3.76" spread="0.285"/>
                    <measurement group_id="O6" value="3.69" spread="0.274"/>
                    <measurement group_id="O7" value="3.55" spread="0.421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final change from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.057"/>
                    <measurement group_id="O2" value="-0.05" spread="0.072"/>
                    <measurement group_id="O3" value="-0.03" spread="0.053"/>
                    <measurement group_id="O4" value="-0.09" spread="0.090"/>
                    <measurement group_id="O5" value="-0.02" spread="0.070"/>
                    <measurement group_id="O6" value="-0.16" spread="0.088"/>
                    <measurement group_id="O7" value="-0.01" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2</title>
        <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
        <time_frame>Day 1 - Day 113</time_frame>
        <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2</title>
          <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
          <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.105" spread="0.0325"/>
                    <measurement group_id="O2" value="-0.360" spread="0.3752"/>
                    <measurement group_id="O3" value="-0.279" spread="0.0988"/>
                    <measurement group_id="O4" value="-0.495" spread="0.2093"/>
                    <measurement group_id="O5" value="-0.394" spread="0.1586"/>
                    <measurement group_id="O6" value="-0.336" spread="0.1685"/>
                    <measurement group_id="O7" value="-0.101" spread="0.0714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Time to Maximum qHBsAg Decrease on Day 1-113 - Part 2</title>
        <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
        <time_frame>Day 1 - Day 113</time_frame>
        <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Time to Maximum qHBsAg Decrease on Day 1-113 - Part 2</title>
          <description>HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.</description>
          <population>Participants that did not complete planned treatment and/or discontinued from the study were not included in this end point.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.5" lower_limit="35" upper_limit="113"/>
                    <measurement group_id="O2" value="43.0" lower_limit="36" upper_limit="43"/>
                    <measurement group_id="O3" value="43.0" lower_limit="36" upper_limit="85"/>
                    <measurement group_id="O4" value="43.0" lower_limit="29" upper_limit="113"/>
                    <measurement group_id="O5" value="39.5" lower_limit="36" upper_limit="85"/>
                    <measurement group_id="O6" value="61.0" lower_limit="29" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2</title>
        <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
        <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2</title>
          <description>Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF &gt; 500 msec, or &gt; 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="85.7"/>
                    <measurement group_id="O6" value="75.0"/>
                    <measurement group_id="O7" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="64.3"/>
                    <measurement group_id="O5" value="57.1"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="57.1"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O6" value="75.0"/>
                    <measurement group_id="O7" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="75.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 23 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O7" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="64.3"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O7" value="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O7" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="64.3"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O7" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O7" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="75.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="57.1"/>
                    <measurement group_id="O7" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="57.1"/>
                    <measurement group_id="O5" value="71.4"/>
                    <measurement group_id="O7" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="57.1"/>
                    <measurement group_id="O7" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="42.9"/>
                    <measurement group_id="O5" value="71.4"/>
                    <measurement group_id="O7" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1</title>
        <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single SC injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Placebo</title>
            <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1</title>
          <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 12h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 - 168h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1</title>
        <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 - RO7062931 0.1 mg/kg</title>
            <description>Participants received a single SC injection of 0.1 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 1 - RO7062931 0.3 mg/kg</title>
            <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 1 - RO7062931 1.0 mg/kg</title>
            <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 1 - RO7062931 2.0 mg/kg</title>
            <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 1 - RO7062931 3.0 mg/kg</title>
            <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 1 - RO7062931 4.0 mg/kg</title>
            <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 1 - Placebo</title>
            <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1</title>
          <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 12h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 - 168h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="12.5"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extended Follow-Up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2</title>
        <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2</title>
          <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 23 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2</title>
        <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2</title>
          <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 23 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O7" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2</title>
        <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
        <time_frame>Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113</time_frame>
        <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
            <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O2">
            <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
          </group>
          <group group_id="O3">
            <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
            <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O4">
            <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
            <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O5">
            <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
            <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O6">
            <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
            <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Placebo</title>
            <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2</title>
          <description>Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.</description>
          <population>Safety population: All study subjects that received at least one dose of study medication, whether prematurely withdrawn from the study or not.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="25.0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 23 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 1h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 4h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 - 8h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 30 - 24h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="7.1"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O7" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 106</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up Day 113</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="14.3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 32 months</time_frame>
      <desc>An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and does not necessarily require a causal relationship with treatment. An adverse event can be any unfavorable and unintended sign, symptom, or disease temporally associated with use of a pharmaceutical product, whether or not considered related to the product. Preexisting conditions that worsen during a study are also considered adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1 - RO7062931 0.1 mg/kg</title>
          <description>Participants received a single subcutaneous (SC) injection of 0.1 mg/kg RO7062931.</description>
        </group>
        <group group_id="E2">
          <title>Part 1 - RO7062931 0.3 mg/kg</title>
          <description>Participants received a single SC injection of 0.3 mg/kg RO7062931.</description>
        </group>
        <group group_id="E3">
          <title>Part 1 - RO7062931 1.0 mg/kg</title>
          <description>Participants received a single SC injection of 1.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E4">
          <title>Part 1 - RO7062931 2.0 mg/kg</title>
          <description>Participants received a single SC injection of 2.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E5">
          <title>Part 1 - RO7062931 3.0 mg/kg</title>
          <description>Participants received a single SC injection of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E6">
          <title>Part 1 - RO7062931 4.0 mg/kg</title>
          <description>Participants received a single SC injection of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E7">
          <title>Part 1 - Placebo</title>
          <description>Participants received a single SC injection of placebo matched to RO7062931.</description>
        </group>
        <group group_id="E8">
          <title>Part 2a - RO7062931 0.5 mg/kg Q1M</title>
          <description>Participants received two QM SC injections of 0.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="E9">
          <title>Part 2a - RO7062931 1.5 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 1.5 mg/kg RO7062931.</description>
        </group>
        <group group_id="E10">
          <title>Part 2a - RO7062931 3.0 mg/kg Q1M</title>
          <description>Participants received 2 QM SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E11">
          <title>Part 2b - RO7062931 3.0 mg/kg QW</title>
          <description>Participants received five QW SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E12">
          <title>Part 2b - RO7062931 3.0 mg/kg Q2W</title>
          <description>Participants received three Q2W SC injections of 3.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E13">
          <title>Part 2b - RO7062931 4.0 mg/kg QW</title>
          <description>Participants received four QW SC injections of 4.0 mg/kg RO7062931.</description>
        </group>
        <group group_id="E14">
          <title>Part 2 - Placebo</title>
          <description>Participants received SC placebo matched to RO7062931 over a 4-week period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E14" subjects_affected="8" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Catheter site thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle feacture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03038113
org study id: BP39405
nct id: NCT03038113
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
This randomized study will be conducted in two parts to evaluate the safety, tolerability,
      pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931. Part 1
      will include only healthy participants and Part 2 will include only participants with chronic
      hepatitis B (CHB). Part 1 is an adaptive, single-ascending dose study with an adaptive
      dose-escalating schedule to determine the best dose to be evaluated in participants with CHB.
      Part 2 is an adaptive, parallel multiple-dose study comprised of three sub-parts which will
      be used to further refine the dose and dosing regimen, and to evaluate the safety and
      efficacy of RO7062931 when administered with standard-of-care (SoC) therapy.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Basic Science
masking: Double (Participant, Investigator)
measure: Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest
time frame: Up to day 113
description: An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation ≥10x ULN, v.) creatinine elevation ≥1.5x ULN or ≥50% from baseline.
measure: Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1
time frame: Screening, Days -1, 2, 8, 15, 29, 85
description: Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.
measure: Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2
time frame: Screening, Days -1, 2, 8, 15, 29, at discontinuation, Days 36, 43, 57, 85, 113
description: Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.
measure: Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1
time frame: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
description: Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF > 500 msec, or > 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.
measure: Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2
time frame: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
description: Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF > 500 msec, or > 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.
measure: Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1
time frame: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
description: Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
measure: Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1
time frame: Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
description: Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
measure: Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2
time frame: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
description: Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
measure: Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2
time frame: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
description: Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
measure: Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2
time frame: Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
description: Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
measure: Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1
time frame: Days 1-8
description: Cmax values are the the peak plasma concentration reached after administration of RO7062931.
measure: Cmax After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: Cmax values are the the peak plasma concentration reached after administration of RO7062931.
measure: Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1
time frame: Days 1-8
description: Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.
measure: Tmax After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.
measure: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1
time frame: Days 1-8
description: AUC0-inf was calculated based on non-compartmental analysis.
measure: AUC0-inf After Multiple Ascending Doses - Part 2
time frame: Days 1,22,29
description: AUC0-inf was calculated based on non-compartmental analysis.
measure: Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1
time frame: Days 1-8
description: AUC0-last was calculated based on non-compartmental analysis.
measure: AUC0-last After Multiple Ascending Doses - Part 2
time frame: Days 1,22,29
description: AUC0-last was calculated based on non-compartmental analysis.
measure: Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1
time frame: Days 1-8
description: T1/2 was calculated based on non-compartmental analysis.
measure: Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: T1/2 was calculated based on non-compartmental analysis.
measure: Total Clearance (CL) After Single Ascending Doses - Part 1
time frame: Days 1-8
description: Apparent oral clearance was calculated from Dose/AUCinf.
measure: Total Clearance (CL) After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: Apparent oral clearance was calculated from Dose/AUCinf.
measure: Volume of Distribution (Vss) After Single Ascending Doses - Part 1
time frame: Days 1-8
description: Vss was calculated from dose/AUCinf
measure: Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: Vss was calculated from dose/AUCinf
measure: Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1
time frame: Hours 0-4, 0-8, 0-12, and 0-24
description: Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.
measure: Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.
measure: Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2
time frame: Days 1-113
description: HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
measure: Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2
time frame: Day 1 - Day 113
description: HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
measure: Summary of Time to Maximum qHBsAg Decrease on Day 1-113 - Part 2
time frame: Day 1 - Day 113
description: HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
arm group label: Part 1: Single-Ascending Dose (SAD)
arm group type: Experimental
description: Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
arm group label: Part 2: Multiple Ascending Dose
arm group type: Experimental
description: Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
intervention type: Drug
intervention name: RO7062931
description: Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
arm group label: Part 1: Single-Ascending Dose (SAD)
arm group label: Part 2: Multiple Ascending Dose
intervention type: Drug
intervention name: Placebo
description: Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
arm group label: Part 1: Single-Ascending Dose (SAD)
arm group label: Part 2: Multiple Ascending Dose
intervention type: Drug
intervention name: Immune Modulator
description: Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
arm group label: Part 2: Multiple Ascending Dose
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: Accepts Healthy Volunteers
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: Hong Kong
country: Korea, Republic of
country: New Zealand
country: Singapore
country: Taiwan
country: Thailand
responsible party type: Sponsor
mesh term: Hepatitis A
mesh term: Hepatitis B
mesh term: Hepatitis B, Chronic
mesh term: Hepatitis
mesh term: Hepatitis, Chronic
mesh term: Immunomodulating Agents
sharing ipd: No
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 